New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Ibrance (palbociclib) - Drug Insight and Market Forecast - 2030 ...

The breast cancer medication Ibrance has been the shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to raise the entire company’s fortunes. That’s despite Ibrance’s ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...

It’s unusual to have the FDA chase down a pharma company and ask them apply for a new drug indication. But Pfizer went through just that and has now quietly revealed a label expansion for blockbuster ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The anticipated approval of Ibrance (palbociclib) came two months ahead of expectations, as the FDA granted an accelerated approval to the drug as a frontline treatment for women with ER-positive, ...

Ibrance gained full FDA approval for the treatment of some patients with breast cancer. Ibrance (palbociclib) was granted full FDA approval for use in combination with letrozole (Femara) in the ...

Ibrance, made by Pfizer, is a new breast cancer drug hailed as a potential blockbuster. Above, the Pfizer logo is seen at world headquarters in New York, April 28, 2014. Reuters/Andrew Kelly Ibrance, ...

Pfizer’s Ibrance has been approved for use by the NHS in England as a second-line treatment for advanced breast cancer after hormonal therapy, catching up with rival drugs in the class. The decision ...

Pfizer's Ibrance will now be available to male patients with metastatic breast cancer. The US Food and Drug Administration (FDA) has extended its indication for Ibrance (palbociclib) in metastatic ...

NICE has rejected Pfizer’s Ibrance breast cancer drug in first draft guidance, citing the treatment's high cost. The decision confirms the company’s fears that the drug would fare badly under the cost ...